Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States

被引：0
|
作者：
Zakharia, Yousef
Vlahiotis, Anna
Siu, Gordon
Rao, Dharanija
Teresi, Rosemary
Eccleston, Anthony
机构：
[1] Univ Iowa, Iowa City, IA USA
[2] Pfizer, New York, NY USA
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Inc, Mentor, OH USA
[5] Pfizer Inc, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16553
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordan
    Levin, Rebecca
    Vlahiotis, Anna
    Zanotti, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordon
    Levin, Rebecca
    Vlahiotis, Anna
    Rao, Dharanija
    Zanotti, Giovanni
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [4] Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
    Harada, Ken-ichi
    Sato, Ryo
    Bando, Yukari
    Sano, Asuka
    Matsushita, Yuto
    Tamura, Keita
    Terakawa, Tomoaki
    Furukawa, Junya
    Fujimoto, Naohiro
    Fujisawa, Masato
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 772 - 777
  • [5] Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
    Beaulieu, Carissa
    Ghosh, Sunita
    Tajzler, Camilla
    Kirkpatrick, Mckayla
    Castonguay, Vincent
    Wood, Lori
    Graham, Jeffrey
    Soulieres, Denis
    Bansal, Rahul K.
    Heng, Daniel Yick Chin
    Finelli, Antonio
    Tanguay, Simon
    Lalani, Aly-Khan A.
    Bhindi, Bimal
    Bjarnason, Georg A.
    Breau, Rodney H.
    Basappa, Naveen S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 382 - 382
  • [6] Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
    Kondo, Tsunenori
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 777 - 778
  • [7] Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
    Doshi, Gurjyot K.
    Osterland, Andrew J.
    Shi, Ping
    Yim, Annette
    Del Tejo, Viviana
    Guttenplan, Sarah B.
    Eiffert, Samantha
    Yin, Xin
    Rosenblatt, Lisa
    Conkling, Paul R.
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [8] Avelumab plus axitinib for first-line treatment of advanced renal cell carcinoma: A real-world ambispective RAVE-Renal study.
    Chubenko, Viacheslav
    Baklanova, Olga
    Kalpinskiy, Alexey
    Safina, Sufiia
    Lebedinets, Andrey
    Shkurat, Alexey
    Parsadanova, Elvira
    Turganova, Maria
    Petkau, Vladislav
    Tovbik, Natalya
    Tkacheva, Elena
    Anzhiganova, Yulia
    Novikova, Olga
    Bragina, Varvara
    Zukov, Ruslan
    Tsimafeyeu, Ilya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 117 - 117
  • [9] First-line Axitinib plus Pembrolizumab in advanced renal cell carcinoma: retrospective real world data from a multicentre patient cohort
    Darr, Christopher
    Stelmach, Ramona
    Schlack, Katrin
    Dinkel, Hendrik
    Paffenholz, Pia
    Ivanyi, Philipp
    Wiegmann, Jonas
    Schulz, Anton
    Kramer, Mario
    Schnabel, Marco
    Rinderknecht, Emily
    Handke, Analena
    Hilser, Thomas
    Heidenreich, Axel
    Hadaschik, Boris
    Zschaebitz, Stefanie
    Gruenwald, Viktor
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 79 - 80
  • [10] Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    Dong, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1559 - S1560
12345